0001193125-22-284534.txt : 20221114 0001193125-22-284534.hdr.sgml : 20221114 20221114160358 ACCESSION NUMBER: 0001193125-22-284534 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 EFFECTIVENESS DATE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: APPLIED GENETIC TECHNOLOGIES CORP CENTRAL INDEX KEY: 0001273636 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 593553710 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36370 FILM NUMBER: 221385009 BUSINESS ADDRESS: STREET 1: 14193 NW 119TH TERRACE STREET 2: SUITE #10 CITY: ALACHUA STATE: FL ZIP: 32615 BUSINESS PHONE: 386-462-2204 MAIL ADDRESS: STREET 1: 14193 NW 119TH TERRACE STREET 2: SUITE #10 CITY: ALACHUA STATE: FL ZIP: 32615 NT 10-Q 1 d397426dnt10q.htm NT 10-Q NT 10-Q
SEC FILE NUMBER: 001-36370
CUSIP NUMBER: 03820J100

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 12b-25

 

 

NOTIFICATION OF LATE FILING

 

(Check One):      

☐  Form 10-K     ☐  Form 20-F     ☐  Form 11-K     ☒  Form 10-Q

☐  Form 10-D     ☐  Form N-CEN     ☐  Form N-CSR

  For Period Ended: September 30, 2022
  ☐  Transition Report on Form 10-K
  ☐  Transition Report on Form 20-F
  ☐  Transition Report on Form 11-K
  ☐  Transition Report on Form 10-Q
  For the Transition Period Ended:     

 

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

 

 

PART I — REGISTRANT INFORMATION

Applied Genetic Technologies Corporation

Full name of Registrant

Not Applicable

Former Name if Applicable

14193 NW 119th Terrace, Suite 10

Address of Principal Executive Office (Street and Number)

Alachua, Florida 32615

City, State and Zip Code

 

 

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

 

☒      (a)  

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

  (b)  

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

  (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if Needed)

Applied Genetic Technologies Corporation (the “Company”) was not, without unreasonable effort or expense, able to file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (the “Quarterly Report”) by the prescribed due date for the reasons described below.

Due to human resource constraints and management’s substantive efforts to support the recently announced proposed merger transaction, the Company requires additional time to finalize its unaudited interim financial statements and related disclosures to be included in the Quarterly Report. The Company is working diligently to complete the Quarterly Report and expects to file it on or before November 21, 2022, the expiration of the extension period prescribed by Rule 12b-25.

 

 

PART IV — OTHER INFORMATION

 

(1)          Name and telephone number of person to contact in regard to this notification:
    Jonathan I. Lieber            (617)         

843-5778

    (Name)       (Area Code)     (Telephone Number)
(2)     Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).    Yes  ☒    No  ☐
(3)     Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?    Yes  ☒    No  ☐

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

On July 15, 2022, the Company closed an underwritten public offering of its common stock, together with accompanying warrants. As a result, the Company will recognize (i) approximately $0.5 million of warrant-related costs and expenses during the three months ended September 30, 2022 and (ii) a warrant derivative liability of approximately $3.6 million as of September 30, 2022.

 

 

 

Applied Genetic Technologies Corporation

(Name of Registrant as specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: November 14, 2022     By:   /s/ Jonathan I. Lieber
      Jonathan I. Lieber
      Chief Financial Officer